Skip to main content
Marksans Pharma Ltd. logo

Marksans Pharma Ltd. - Investor Relations & Filings

Listed
Ticker · MARKSANS ISIN · INE750C01026 LEI · 335800YXQPMPSAC51K30 BSE.NS Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2026-03-26 Regulatory Filings
Country IN India
Listing BSE.NS MARKSANS · 2 venues

Key figures FY2026

Period ended 2026-03-31 · INR
Headline annual figures for Marksans Pharma Ltd., fiscal year 2026, reported in INR, with the source filing for each figure.
Total Revenues INR 13.41B per the Annual Report filed 2026-06-26
Net Income INR 3.01B per the Annual Report filed 2026-06-26
Total Assets INR 19.94B per the Annual Report filed 2026-06-26
Total Equity INR 16.52B per the Annual Report filed 2026-06-26
Cash from Ops INR 2.11B per the Annual Report filed 2026-06-26

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Marksans Pharma Ltd.

https://www.marksanspharma.com

Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the closure of the trading window for designated persons in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It specifies the trading window closure period related to the upcoming declaration of audited financial results for the quarter and year ending March 31, 2026. The document does not contain any financial data, results, or detailed report content but is an announcement about trading restrictions ahead of financial results disclosure. The document length is short (1971 characters) and is clearly an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers compliance-related announcements and regulatory notices that do not fit other categories.
2026-03-26 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a copy of a newspaper publication containing a formal notice from Marksans Pharma Limited regarding a newspaper advertisement for the re-lodgement of physical share transfer requests. It also includes general news articles about maritime security and pharmaceutical regulations. As the document is primarily a regulatory disclosure (Regulation 30 of SEBI) regarding the publication of a notice, it falls under the category of general regulatory announcements.
2026-03-12 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a notice from Marksans Pharma Limited addressed to stock exchanges and shareholders regarding the opening of a special window for re-lodgment of transfer requests of physical shares. It references a SEBI circular and provides instructions and contact details for shareholders to re-lodge transfer deeds for shares purchased/sold prior to April 1, 2019. The document is informational and regulatory in nature, notifying shareholders about a procedural facilitation by the regulator. It does not contain financial statements, management discussion, earnings data, or any report publication. It is not a report itself but a regulatory announcement related to shareholder rights and transfer procedures. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-03-11 English
General Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the company's participation in an upcoming conference (Investec India Promoter & Founder Conference 2026). It explicitly states no unpublished price-sensitive information will be discussed and is submitted pursuant to a listing regulation. The document does not contain any financial data, report content, or detailed presentation materials. It is an announcement of an event rather than a report or transcript. Given the nature and length of the document, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Investor Presentation or Call Transcript.
2026-03-10 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Marksans Pharma Limited, specifically for Q3 and 9 months of fiscal year 2026. It includes management commentary on financial results, revenue growth, market performance, product approvals, strategic expansions, and a Q&A session with analysts. The presence of detailed financial figures, discussion of quarterly and nine-month performance, and forward-looking statements about business outlook clearly identify this as a Call Transcript (CT). The document is lengthy (15,000 characters) and contains the full text of the call, not just an announcement or summary, so it is not an Earnings Release (ER) or Report Publication Announcement (RPA). Therefore, the appropriate classification is Call Transcript (CT) with high confidence.
2026-02-12 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 06 February 2026 from Marksans Pharma Limited addressed to stock exchanges. It informs that the audio recording of the investor/analyst conference call on Q3 & 9M FY26 financial results has been uploaded on the company's website. The document does not contain the transcript itself, financial data, or detailed analysis, but merely notifies the availability of the recording. The length is only 1523 characters, which is quite short and consistent with an announcement rather than a full transcript or report. According to the rules, announcements about availability of conference call recordings or transcripts are classified as Regulatory Filings (RNS) rather than Call Transcript (CT) or Interim Report (IR). Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.